Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02323867 | Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies(AB-CliniMACs) | active not recruiting | Phase 2 | 140 | Children's Hospital of PhiladelphiaOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05236764 | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion(HAPLOTAB) | active not recruiting | N/A | 3 | Baylor College of MedicineOTHER | 1 |
| Oct 30, 2025 |
| clinicaltrials |
| NCT02756962 | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | active not recruiting | Phase 2 | 107 | Washington University School of MedicineOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT03513484 | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 44 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT07204366 | Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study) | active not recruiting | — | 219 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2(REGAL) | active not recruiting | Phase 3 | 127 | Sellas Life Sciences GroupINDUSTRY | 10 | Oct 1, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT03731260 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | active not recruiting | Phase 2 | 251 | Blueprint Medicines CorporationINDUSTRY | 13 | Sep 23, 2025 | clinicaltrials |
| NCT04378855 | Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).(PROPHECY) | active not recruiting | — | 572 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07187505 | Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia | active not recruiting | N/A | 28 | Anhui Medical UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02917720 | 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients(NAUT) | active not recruiting | Phase 2 | 75 | European LeukemiaNetNETWORK | 2 | Sep 22, 2025 | clinicaltrials |
| NCT04258943 | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 60 | Children's Oncology GroupNETWORK | 8 | Sep 18, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07022743 | Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy | active not recruiting | Phase 2 | 75 | Obafemi Awolowo UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04541056 | Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae | active not recruiting | N/A | 60 | Norwegian University of Science and TechnologyOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
| NCT04822766 | A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia(ALLO-BEST) | active not recruiting | N/A | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | active not recruiting | Phase 3 | 111 | PharmaEssentiaINDUSTRY | 2 | Aug 13, 2025 | clinicaltrials |
| NCT05482971 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | active not recruiting | Phase 2 | 91 | PharmaEssentiaINDUSTRY | 2 | Aug 13, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera(VERIFY) | active not recruiting | Phase 3 | 293 | Protagonist Therapeutics, Inc.INDUSTRY | 20 | Aug 7, 2025 | clinicaltrials |
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera(THRIVE) | active not recruiting | Phase 3 | 46 | Protagonist Therapeutics, Inc.INDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05485948 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | active not recruiting | Phase 2 | 49 | PharmaEssentiaINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT03897127 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | active not recruiting | Phase 3 | 882 | University of UlmOTHER | 2 | Jul 17, 2025 | clinicaltrials |
| NCT04454658 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 14 | Jul 16, 2025 | clinicaltrials |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07060612 | Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA)(HIFA) | active not recruiting | — | 300 | Instituto de Investigacion Sanitaria La FeOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 144 | Foghorn Therapeutics Inc.INDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT01985061 | Evaluation of 3 Different Doses of IV Busulfan(AAA) | active not recruiting | Phase 2 | 177 | Institut Paoli-CalmettesOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT04415008 | Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 61 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03031262 | Efficacy and Safety of Chidamide in CBF Leukemia | active not recruiting | Phase 1 / Phase 2 | 250 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05356169 | Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | active not recruiting | Phase 2 / Phase 3 | 312 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT04202835 | ATG Plus PTCy vs ATG for CGVHD Prophylaxis | active not recruiting | Phase 2 | 80 | McMaster UniversityOTHER | 2 | May 11, 2025 | clinicaltrials |
| NCT01761968 | Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | active not recruiting | Phase 2 | 90 | ItalfarmacoINDUSTRY | 3 | Apr 30, 2025 | clinicaltrials |
| NCT04232241 | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | active not recruiting | Phase 2 | 167 | Universitätsklinikum Hamburg-EppendorfOTHER | 7 | Apr 22, 2025 | clinicaltrials |
| NCT04233346 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | active not recruiting | Phase 2 | 93 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06065007 | Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis | active not recruiting | — | 400 | Uppsala UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03918655 | MIF Involvement in AML(MIFAML) | active not recruiting | — | 186 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05883956 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia(PREFER-HMA) | active not recruiting | Phase 3 | 13 | Otsuka Australia Pharmaceutical Pty LtdINDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05434312 | TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients | active not recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03618485 | Registry of Patients With MPNs in Taiwan | active not recruiting | — | 500 | Chang Gung Memorial HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT06452446 | Telehealth-based Symptom Management for Veterans Treated With Selinexor(Selinexor) | active not recruiting | — | 20 | Durham VA Medical CenterFED | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06734078 | An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme(POSS) | active not recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 31, 2025source: clinicaltrials